Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
This is an uncontrolled study without comparator. Subjects were followed up to 4 years on Technosphere Insulin. Of 229 subjects 199 were exposed for ≥12 mo, 175 for ≥ 24 mo, 60 for ≥ 36 mo, 31 for ≥ 42 mo, & 2 for 48 mo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TI Inhalation Powder | Experimental | Technosphere® Insulin Inhalation Powder |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler | Drug | Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U |
| Measure | Description | Time Frame |
|---|---|---|
| Annual Rate of Change in FEV1 From Baseline to End of Study | Baseline to 48 months |
| Measure | Description | Time Frame |
|---|---|---|
| Annual Rate of Change in FVC From Baseline to End of Study | Baseline to 48 months | |
| Annual Rate of Change in DLCo From Baseline to End of Study | Baseline to 48 months | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anders Boss, MD | Mannkind Corporation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dorothy L & James E Frank Diabetes Research Institute | San Mateo | California | 94401 | United States | ||
This was a follow-on trial for subjects who completed one of the two parent trials (PDC-IND-0008 or MKC-TI-005). Inclusion/Exclusion was participation in these parent trials.
First patient enrolled May 31, 2004 Multi-center international trial conducted in USA, Bulgaria, Czech Republic, and Germany. Conducted in medical offices, hospital clinics, and universities.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | TI Inhalation Powder | Technosphere® Insulin Inhalation Powder |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change in HbA1c From Baseline to Last Measurement on Study Drug (Maximum of 48 Months) |
Change in HbA1c from Baseline to last measurement on study drug (maximum of 48 months) |
| Baseline to last measurement on study drug (maximum of 48 months |
| Change in FPG From Baseline to Last Study Measurement on Treatment (Maximum of 48 Months) | Change from Baseline to last study measurement on treatment (maximum of 48 months) | Baseline to last study measurement on treatment (maximum of 48 months) |
| Change in Weight in kg From Baseline to End of Study | Baseline to last measurement on study drug (maximum of 48 months) | Baseline to last measurement on study drug (maximum of 48 months) |
| High Resolution Computerized Tomography Scans of the Chest | End of study |
| Sansum Medical Research Institute |
| Santa Barbara |
| California |
| 93105 |
| United States |
| Alliance Medical Group of Greater Waterbury | Middlebury | Connecticut | 06762 | United States |
| The Hospital of Central Connecticut | New Britain | Connecticut | 06050 | United States |
| Soundview Research Associates | Norwalk | Connecticut | 06851 | United States |
| University of Miami School of Medicine | Miami | Florida | 33136 | United States |
| Oschner Clinic Foundation | New Orleans | Louisiana | 70121 | United States |
| International Diabetes Center | Minneapolis | Minnesota | 55416 | United States |
| Diabetes Care & Information Center of New York | Flushing | New York | 11365 | United States |
| Diabetes Team Associated | New York | New York | 10016 | United States |
| Endocrine Research - Physician's East PA | Greenville | North Carolina | 27834 | United States |
| Your Diabetes Endocrine Nutrition Group | Mentor | Ohio | 44060 | United States |
| Dallas Diabetes & Endocrine Center | Dallas | Texas | 75230 | United States |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | United States |
| Texas Diabetes Institute | San Antonio | Texas | 78207 | United States |
| Diabetes & Glandular Disease Research Assoc PA | San Antonio | Texas | 78229 | United States |
| Diabetes Care Center | Seattle | Washington | 98105 | United States |
| MBAL "Pleven" | Pleven | BGR | 5800 | Bulgaria |
| SBALENG-Sofia Institute of Endocrinology | Sofia | BGR | 1303 | Bulgaria |
| MBAL Alexandrovska Hospital | Sofia | BGR | 1431 | Bulgaria |
| Military Medical Academy | Sofia | BGR | 1431 | Bulgaria |
| Central Clinical Base | Sofia | BGR | 1606 | Bulgaria |
| MBAL "Sweta Marina" - Varna | Varna | BGR | 5000 | Bulgaria |
| II-nd MBAL | Sofia | Sofia | 1202 | Bulgaria |
| Military Medical Academy | Sofia | 1431 | Bulgaria |
| Military Hospital in Brno | Brno | CZE | 636 00 | Czechia |
| Hospital of "Milosrdnych brain" | Brno | CZE | 639 00 | Czechia |
| University Hospital in Brno | Brno-Bohunice | CZE | 625 00 | Czechia |
| Surgery of Diabetology | Mělník | CZE | 276 01 | Czechia |
| University Hospital of 3rd Faculty | Prague | CZE | 100 34 | Czechia |
| Surgery of Diabetology Petrovice | Prague | CZE | 109 00 | Czechia |
| Diabetologicka oridnace | Prague | CZE | 120 00 | Czechia |
| General Hospital in Prague and 1st Faculty of Medicine of | Prague | CZE | 120 00 | Czechia |
| Institute for Clinical and Exp Medicine | Prague | CZE | 140 21 | Czechia |
| Surgery of Diabetology Stodulky | Prague | CZE | 155 00 | Czechia |
| University Hospital Na Bulovce | Prague | CZE | 180 81 | Czechia |
| Surgery of Diabetology Slany | Slaný | CZE | 274 01 | Czechia |
| Surgery of Diabetology Zastavka | Zastavka, Brno | CZE | 664 84 | Czechia |
| Surgery of Diabetology (Brno) | Brno | 612 00 | Czechia |
| ikfe Berlin | Berlin | DEU | D 10115 | Germany |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | TI Inhalation Powder | Technosphere® Insulin Inhalation Powder |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Full Range | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| DLCo | Lung Diffusion Capacity | Mean | Standard Deviation | mL/min/mmHg |
| ||||||||||||||||
| FEV1 | Forced Expiratory Volumne in 1 sec. | Mean | Standard Deviation | Liters |
| ||||||||||||||||
| FPG | Fasting Plasma Glucose | Mean | Standard Deviation | mg/dL |
| ||||||||||||||||
| FVC | Forced Vital Capacity | Mean | Standard Deviation | Liters |
| ||||||||||||||||
| HbA1c | Glycosylated Hemoglobin | Mean | Standard Deviation | % |
| ||||||||||||||||
| Weight | Weight in kg | Mean | Standard Deviation | kg |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Annual Rate of Change in FEV1 From Baseline to End of Study | Safety Population defined as all subjects who received at least one dose of study drug | Posted | Mean | Standard Error | Liters per year | Baseline to 48 months |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Annual Rate of Change in FVC From Baseline to End of Study | Safety | Posted | Mean | Standard Error | Liters per year | Baseline to 48 months |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Annual Rate of Change in DLCo From Baseline to End of Study | Safety | Posted | Mean | Standard Error | mL/min/mmHg per year | Baseline to 48 months |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change in HbA1c From Baseline to Last Measurement on Study Drug (Maximum of 48 Months) | Change in HbA1c from Baseline to last measurement on study drug (maximum of 48 months) | Safety | Posted | Mean | Standard Deviation | percentage | Baseline to last measurement on study drug (maximum of 48 months |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change in FPG From Baseline to Last Study Measurement on Treatment (Maximum of 48 Months) | Change from Baseline to last study measurement on treatment (maximum of 48 months) | Posted | Mean | Standard Deviation | milligrams per deciliter | Baseline to last study measurement on treatment (maximum of 48 months) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change in Weight in kg From Baseline to End of Study | Baseline to last measurement on study drug (maximum of 48 months) | Safety | Posted | Mean | Standard Deviation | kilograms | Baseline to last measurement on study drug (maximum of 48 months) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | High Resolution Computerized Tomography Scans of the Chest | participants in Safety population with available post-baseline data | Posted | Number | participants | End of study |
|
|
|
May 31, 2004 to June 5, 2008
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | TI Inhalation Powder | Technosphere® Insulin Inhalation Powder | 30 | 229 | 156 | 229 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Microcytic anaemia | Blood and lymphatic system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Myocardial ischaemia | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Acute myocardial infarction | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Atrioventricular block complete | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Cardio-respiratory arrest | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Cardiovascular disorder | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Cataract | Eye disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Appendicitis | Infections and infestations | MedDRA 7.1 | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA 7.1 | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA 7.1 | Systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA 7.1 | Systematic Assessment |
| |
| Device failure | Injury, poisoning and procedural complications | MedDRA 7.1 | Systematic Assessment |
| |
| Thermal burn | Injury, poisoning and procedural complications | MedDRA 7.1 | Systematic Assessment |
| |
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Hypoglycaemic seizure | Metabolism and nutrition disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Localised osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 7.1 | Systematic Assessment |
| |
| Colon adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 7.1 | Systematic Assessment |
| |
| Meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 7.1 | Systematic Assessment |
| |
| Pancreatic carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 7.1 | Systematic Assessment |
| |
| Prostate cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 7.1 | Systematic Assessment |
| |
| Prostatic adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 7.1 | Systematic Assessment |
| |
| Renal cell carcinoma stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 7.1 | Systematic Assessment |
| |
| Ataxia | Nervous system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Diabetic neuropathy | Nervous system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Vertebrobasilar insufficiency | Nervous system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Calculus ureteric | Renal and urinary disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Renal failure acute | Renal and urinary disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Aortic aneurysm | Vascular disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Arterial stenosis | Vascular disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Deep vein thrombosis | Vascular disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 7.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cataract | Eye disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Diabetic retinopathy | Eye disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 7.1 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 7.1 | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA 7.1 | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA 7.1 | Systematic Assessment |
| |
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Hypercholesterolaemia | Metabolism and nutrition disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Hypertriglyceridaemia | Metabolism and nutrition disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Productive cough | Respiratory, thoracic and mediastinal disorders | MedDRA 7.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 7.1 | Systematic Assessment |
|
MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Medical Officer | MannKind Corporation | 201-983-5000 | aboss@mannkindcorp.com |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
|
|
|
|
| Title | Denominators | Categories |
|---|
|
| Title |
|---|
| Denominators |
|---|
| Categories |
|---|
|
| Title |
|---|
| Denominators |
|---|
| Categories |
|---|
|
| "Normal" HRCT subjects |
|
| "Abnormal, clinically not significant" subjects |
|
| "Abnormal, Clinically Significant" HRCT subjects |
|